Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 86 articles:
HTML format
Text format



Single Articles


    March 2017

  1. Correction: Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Cancer Res. 2017;77:1505.
    PubMed     Text format    


    February 2017
  2. STEINBERG SM, Shabaneh T, Zhang P, Martyanov V, et al
    Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.1755.2016.
    PubMed     Text format     Abstract available


    January 2017
  3. ZHANG T, Xu M, Makowski MM, Lee C, et al
    SDHD promoter mutations ablate GABP transcription factor binding in melanoma.
    Cancer Res. 2017 Jan 20. pii: canres.0919.2016.
    PubMed     Text format     Abstract available


  4. NEUBERT NJ, Tille L, Barras D, Soneson C, et al
    Broad and conserved immune regulation by genetically heterogeneous melanoma cells.
    Cancer Res. 2017 Jan 19. pii: canres.2680.2016.
    PubMed     Text format     Abstract available


    November 2016
  5. JOYCE CE, Yanez AG, Mori A, Yoda A, et al
    Differential regulation of the melanoma proteome by eIF4A1 and eIF4E.
    Cancer Res. 2016 Nov 22. pii: canres.1298.2016.
    PubMed     Text format     Abstract available


    September 2016
  6. XIA T, Konno H, Barber GN
    Recurrent loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
    Cancer Res. 2016 Sep 28. pii: canres.1404.2016.
    PubMed     Text format     Abstract available


  7. KIM M, Neznanov N, Wilfong CD, Fleyshman DI, et al
    Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas.
    Cancer Res. 2016 Sep 28. pii: canres.2764.2015.
    PubMed     Text format     Abstract available


  8. SATOW R, Nakamura T, Kato C, Endo M, et al
    ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3.
    Cancer Res. 2016 Sep 26. pii: canres.0991.2016.
    PubMed     Text format     Abstract available


  9. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available


  10. KLARQUIST J, Tobin K, Farhangi Oskuei P, Henning SW, et al
    CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA.
    Cancer Res. 2016 Sep 12. pii: canres.0618.2016.
    PubMed     Text format     Abstract available


    August 2016
  11. TEH JL, Purwin TJ, Greenawalt EJ, Chervoneva I, et al
    An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma.
    Cancer Res. 2016 Aug 3. pii: canres.3384.2015.
    PubMed     Text format     Abstract available


    June 2016
  12. ORSO F, Quirico L, Virga F, Penna E, et al
    miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer.
    Cancer Res. 2016 Jun 21. pii: canres.1322.2015.
    PubMed     Text format     Abstract available


  13. BAKDASH G, Buschow SI, Gorris M, Halilovic A, et al
    Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines.
    Cancer Res. 2016 Jun 20. pii: canres.1695.2015.
    PubMed     Text format     Abstract available


  14. BOYLE SE, Fedele CG, Corbin V, Wybacz E, et al
    CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  15. ZHAO F, Sucker A, Horn S, Heeke C, et al
    Melanoma lesions independently acquire T-cell resistance during metastatic latency.
    Cancer Res. 2016 Jun 3. pii: canres.0008.2016.
    PubMed     Text format     Abstract available


  16. SCHWARTZ H, Blacher E, Amer M, Livneh N, et al
    Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation.
    Cancer Res. 2016 Jun 3. pii: canres.0485.2016.
    PubMed     Text format     Abstract available


    May 2016
  17. HARBST K, Lauss M, Cirenajwis H, Isaksson K, et al
    Multi-region whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma.
    Cancer Res. 2016 May 23. pii: canres.3476.2016.
    PubMed     Text format     Abstract available


  18. LAZAR I, Clement E, Dauvillier S, Milhas D, et al
    Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer.
    Cancer Res. 2016 May 23. pii: canres.0651.2016.
    PubMed     Text format     Abstract available


  19. YAMADA K, Uchiyama A, Uehara A, Perera B, et al
    MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages.
    Cancer Res. 2016 May 17. pii: canres.2812.2015.
    PubMed     Text format     Abstract available


  20. HOLLANDER L, Guo X, Velazquez H, Chang J, et al
    Renalase expression by melanoma and tumor associated-macrophages promotes tumor growth through a STAT3-mediated mechanism.
    Cancer Res. 2016 May 9. pii: canres.1524.2015.
    PubMed     Text format     Abstract available


    April 2016
  21. NEVALA WK, Buhrow SA, Knauer DJ, Reid JM, et al
    Antibody Targeted Chemotherapy for the Treatment of Melanoma.
    Cancer Res. 2016 Apr 28. pii: canres.3131.2015.
    PubMed     Text format     Abstract available


  22. WEBER CE, Luo C, Hotz-Wagenblatt A, Gardyan A, et al
    miR-339-3p is a tumor suppressor in melanoma.
    Cancer Res. 2016 Apr 15. pii: canres.2932.2015.
    PubMed     Text format     Abstract available


  23. MENGER L, Sledzinska A, Bergerhoff K, Vargas FA, et al
    TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
    Cancer Res. 2016;76:2087-93.
    PubMed     Text format     Abstract available


  24. VASATURO A, Halilovic A, Bol KF, Verweij DI, et al
    T cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines.
    Cancer Res. 2016 Apr 11. pii: canres.3211.2015.
    PubMed     Text format     Abstract available


    March 2016
  25. SHOSHAN E, Braeuer RR, Kamiya T, Mobley AK, et al
    NFAT1 directly regulates IL-8 and MMP-3 to promote melanoma tumor growth and metastasis.
    Cancer Res. 2016 Mar 24. pii: canres.2511.2015.
    PubMed     Text format     Abstract available


  26. YOSHIDA A, Lee EK, Diehl JA
    Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended Inhibition of CDK4/6.
    Cancer Res. 2016 Mar 17. pii: canres.2931.2015.
    PubMed     Text format     Abstract available


  27. BUDINA-KOLOMETS A, Webster MR, Leu JI, Jennis M, et al
    HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors.
    Cancer Res. 2016 Mar 16. pii: canres.2137.2015.
    PubMed     Text format     Abstract available


  28. KRUMM A, Barckhausen C, Kucuk P, Tomaszowski KH, et al
    Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2 triggered drug resistance.
    Cancer Res. 2016 Mar 15. pii: canres.2680.2015.
    PubMed     Text format     Abstract available


  29. CONERY AR, Centore RC, Spillane KL, Follmer NE, et al
    Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
    Cancer Res. 2016;76:1313-9.
    PubMed     Text format     Abstract available


    February 2016
  30. NWANI NG, Deguiz ML, Jimenez B, Vinokour E, et al
    Melanoma cells block PEDF production in fibroblasts to induce the tumor-promoting phenotype of cancer-associated fibroblasts.
    Cancer Res. 2016 Feb 26. pii: canres.2468.2015.
    PubMed     Text format     Abstract available


  31. BRENTVILLE VA, Metheringham RL, Gunn B, Symonds P, et al
    Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.
    Cancer Res. 2016;76:548-60.
    PubMed     Text format     Abstract available


    January 2016
  32. BONYADI RAD E, Hammerlindl H, Wels C, Popper U, et al
    Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors.
    Cancer Res. 2016 Jan 22. pii: canres.1722.2015.
    PubMed     Text format     Abstract available


  33. TANAKA M, Shimamura S, Kuriyama S, Maeda D, et al
    SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression.
    Cancer Res. 2016;76:358-69.
    PubMed     Text format     Abstract available


  34. MEIER C, Hardtstock P, Joost S, Alla V, et al
    p73 and IGF1R Regulate Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control.
    Cancer Res. 2016;76:197-205.
    PubMed     Text format     Abstract available


  35. PARK WY, Hong BJ, Lee J, Choi C, et al
    H3K27 Demethylase JMJD3 Employs the NF-kappaB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
    Cancer Res. 2016;76:161-70.
    PubMed     Text format     Abstract available


    December 2015
  36. KOGUCHI Y, Hoen HM, Bambina SA, Rynning MD, et al
    Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
    Cancer Res. 2015;75:5084-92.
    PubMed     Text format     Abstract available


    November 2015
  37. FENG Y, Pinkerton AB, Hulea L, Zhang T, et al
    SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  38. HERKERT B, Kauffmann A, Molle S, Schnell C, et al
    Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition.
    Cancer Res. 2015 Nov 17. pii: canres.3358.2014.
    PubMed     Text format     Abstract available


    October 2015
  39. HOLZEL M, Landsberg J, Glodde N, Bald T, et al
    A preclinical model of malignant peripheral nerve sheath tumor-like melanoma is characterized by infiltrating mast cells.
    Cancer Res. 2015 Oct 28. pii: canres.1090.2015.
    PubMed     Text format     Abstract available


  40. HEILMANN S, Ratnakumar K, Langdon EM, Kansler ER, et al
    A Quantitative System for Studying Metastasis Using Transparent Zebrafish.
    Cancer Res. 2015;75:4272-82.
    PubMed     Text format     Abstract available


    September 2015
  41. NOMAN MZ, Janji B, Hu S, Wu JC, et al
    Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210.
    Cancer Res. 2015;75:3771-87.
    PubMed     Text format     Abstract available


  42. MACLEOD AK, McLaughlin LA, Henderson CJ, Wolf CR, et al
    Activation status of the Pregnane X Receptor (PXR) influences Vemurafenib availability in humanized mouse models.
    Cancer Res. 2015 Sep 11. pii: canres.1454.2015.
    PubMed     Text format     Abstract available


  43. BODOGAI M, Moritoh K, Lee-Chang C, Hollander CM, et al
    Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.
    Cancer Res. 2015;75:3456-65.
    PubMed     Text format     Abstract available


  44. JI W, Li Y, He Y, Yin M, et al
    AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.
    Cancer Res. 2015;75:3492-504.
    PubMed     Text format     Abstract available


    August 2015
  45. CHANDRAN SS, Paria BC, Srivastava AK, Rothermel LD, et al
    Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
    Cancer Res. 2015;75:3216-26.
    PubMed     Text format     Abstract available


  46. ADAMS GN, Rosenfeldt L, Frederick M, Miller W, et al
    Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1 and fibrinogen.
    Cancer Res. 2015 Aug 3. pii: canres.0964.2015.
    PubMed     Text format     Abstract available


    July 2015
  47. CAPPARELLI C, Rosenbaum S, Berman-Booty LD, Salhi A, et al
    ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas.
    Cancer Res. 2015 Jul 23. pii: canres.2959.2014.
    PubMed     Text format     Abstract available


  48. DONIA M, Andersen R, Kjeldsen JW, Fagone P, et al
    Aberrant expression of MHC Class II in melanoma attracts inflammatory tumor specific CD4+ T cells which dampen CD8+ T cell antitumor reactivity.
    Cancer Res. 2015 Jul 16. pii: canres.2956.2014.
    PubMed     Text format     Abstract available


    June 2015
  49. HUANG JL, Urtatiz O, Van Raamsdonk CD
    Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice.
    Cancer Res. 2015 Jun 25. pii: canres.3229.2014.
    PubMed     Text format     Abstract available


    May 2015
  50. HEBEISEN M, Schmidt J, Guillaume P, Baumgaertner P, et al
    Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.
    Cancer Res. 2015;75:1983-91.
    PubMed     Text format     Abstract available


  51. GENG D, Kaczanowska S, Tsai A, Younger K, et al
    TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.
    Cancer Res. 2015;75:1959-71.
    PubMed     Text format     Abstract available


  52. BERTRAND F, Rochotte J, Colacios C, Montfort A, et al
    Blocking Tumor Necrosis Factor alpha enhances CD8 T cell-dependent immunity in experimental melanoma.
    Cancer Res. 2015 May 14. pii: canres.2524.2014.
    PubMed     Text format     Abstract available


  53. CHENG H, Terai M, Kageyama K, Ozaki S, et al
    Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma.
    Cancer Res. 2015 May 7. pii: canres.0370.2015.
    PubMed     Text format     Abstract available


    April 2015
  54. SUN Z, Fourcade J, Pagliano O, Chauvin JM, et al
    IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.
    Cancer Res. 2015;75:1635-44.
    PubMed     Text format     Abstract available


  55. SADOK A, McCarthy A, Caldwell J, Collins I, et al
    Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.
    Cancer Res. 2015 Apr 3. pii: canres.2156.2014.
    PubMed     Text format     Abstract available


  56. NAMIKI T, Yaguchi T, Nakamura K, Valencia JC, et al
    NUAK2 amplification coupled with PTEN deficiency promote melanoma development via CDK activation.
    Cancer Res. 2015 Apr 1. pii: canres.3209.2013.
    PubMed     Text format     Abstract available


  57. ALAMINO VA, Mascanfroni ID, Montesinos MM, Gigena N, et al
    Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor beta.
    Cancer Res. 2015;75:1265-74.
    PubMed     Text format     Abstract available


    March 2015
  58. TATTI O, Gucciardo E, Pekkonen P, Holopainen T, et al
    MMP16 mediates a proteolytic switch to promote cell-cell adhesion, collagen alignment, and lymphatic invasion in melanoma.
    Cancer Res. 2015 Mar 25. pii: canres.1923.2014.
    PubMed     Text format     Abstract available


  59. SCHNEGG CI, Yang MH, Ghosh SK, Hsu MY, et al
    Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma.
    Cancer Res. 2015 Mar 13. pii: canres.1855.2014.
    PubMed     Text format     Abstract available


  60. DUDEK-PERIC AM, Ferreira GB, Muchowicz A, Wouters J, et al
    Anti-tumor immunity triggered by melphalan is potentiated by melanoma cell surface associated calreticulin.
    Cancer Res. 2015 Mar 11. pii: canres.2089.2014.
    PubMed     Text format     Abstract available


  61. ULLRICH N, Heinemann A, Nilewski E, Scheffrahn I, et al
    CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patient survival.
    Cancer Res. 2015 Mar 5. pii: canres.1752.2014.
    PubMed     Text format     Abstract available


    February 2015
  62. LIU XY, Lai F, Yan XG, Jiang CC, et al
    RIP1 kinase is an oncogenic driver in melanoma.
    Cancer Res. 2015 Feb 27. pii: canres.2199.2014.
    PubMed     Text format     Abstract available


  63. SCORTEGAGNA M, Lau E, Zhang T, Feng Y, et al
    PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets.
    Cancer Res. 2015 Feb 24. pii: canres.2785.2014.
    PubMed     Text format     Abstract available


  64. LI Y, Luo S, Ma R, Liu J, et al
    Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors.
    Cancer Res. 2015 Feb 24. pii: canres.2615.2014.
    PubMed     Text format     Abstract available


  65. ADINOLFI E, Capece M, Franceschini A, Falzoni S, et al
    Accelerated tumor progression in mice lacking the ATP receptor P2X7.
    Cancer Res. 2015;75:635-44.
    PubMed     Text format     Abstract available


  66. CHEN S, Wang L, Fan J, Ye C, et al
    Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.
    Cancer Res. 2015;75:519-31.
    PubMed     Text format     Abstract available


    January 2015
  67. SHIM HS, Wei M, Brandhorst S, Longo VD, et al
    Starvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells.
    Cancer Res. 2015 Jan 22. pii: canres.2249.2014.
    PubMed     Text format     Abstract available


  68. CROMPTON JG, Sukumar M, Roychoudhuri R, Clever D, et al
    Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.
    Cancer Res. 2015;75:296-305.
    PubMed     Text format     Abstract available


  69. KADAYAKKARA DK, Korrer MJ, Bulte JW, Levitsky HI, et al
    Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.
    Cancer Res. 2015;75:51-61.
    PubMed     Text format     Abstract available


    December 2014
  70. MA B, Herzog EL, Lee CG, Peng X, et al
    Role of Chitinase 3-like-1 and Semaphorin 7A in Pulmonary Melanoma Metastasis.
    Cancer Res. 2014 Dec 15. pii: canres.3339.2013.
    PubMed     Text format     Abstract available


  71. SLANEY CY, Kershaw MH, Darcy PK
    Trafficking of T cells into tumors.
    Cancer Res. 2014;74:7168-74.
    PubMed     Text format     Abstract available


  72. CEKIC C, Day YJ, Sag D, Linden J, et al
    Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cancer Res. 2014;74:7250-9.
    PubMed     Text format     Abstract available


  73. CEKIC C, Linden J
    Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
    Cancer Res. 2014;74:7239-49.
    PubMed     Text format     Abstract available


  74. YANG J, Hawkins OE, Barham W, Gilchuk P, et al
    Myeloid IKKbeta promotes antitumor immunity by modulating CCL11 and the innate immune response.
    Cancer Res. 2014;74:7274-84.
    PubMed     Text format     Abstract available


  75. GOETZ EM, Ghandi M, Treacy DJ, Wagle N, et al
    ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
    Cancer Res. 2014;74:7079-89.
    PubMed     Text format     Abstract available


  76. SAHU RP, Ocana JA, Harrison KA, Ferracini M, et al
    Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.
    Cancer Res. 2014;74:7069-78.
    PubMed     Text format     Abstract available


  77. SOTO-PANTOJA DR, Terabe M, Ghosh A, Ridnour LA, et al
    CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.
    Cancer Res. 2014;74:6771-83.
    PubMed     Text format     Abstract available


    November 2014
  78. VILGELM AE, Pawlikowski JS, Liu Y, Hawkins OE, et al
    Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.
    Cancer Res. 2014 Nov 14. pii: canres.2405.2014.
    PubMed     Text format     Abstract available


  79. WEI F, Yang D, Tewary P, Li Y, et al
    The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant.
    Cancer Res. 2014;74:5989-98.
    PubMed     Text format     Abstract available


    October 2014
  80. HUANG J, Xiao L, Gong X, Shao W, et al
    Cytokine-like molecule CCDC134 contributes to CD8(+) T-cell effector functions in cancer immunotherapy.
    Cancer Res. 2014;74:5734-45.
    PubMed     Text format     Abstract available


    September 2014
  81. COLVIN TA, Gabai VL, Gong J, Calderwood SK, et al
    Hsp70-Bag3 interactions regulate cancer-related signaling networks.
    Cancer Res. 2014;74:4731-40.
    PubMed     Text format     Abstract available


    August 2014
  82. KUGEL CH 3RD, Hartsough EJ, Davies MA, Setiady YY, et al
    Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.
    Cancer Res. 2014;74:4122-32.
    PubMed     Text format     Abstract available


  83. CHENG M, Qian L, Shen G, Bian G, et al
    Microbiota modulate tumoral immune surveillance in lung through a gammadeltaT17 immune cell-dependent mechanism.
    Cancer Res. 2014;74:4030-41.
    PubMed     Text format     Abstract available


  84. DENG J, Yuan S, Pennati A, Murphy J, et al
    Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.
    Cancer Res. 2014;74:4133-44.
    PubMed     Text format     Abstract available


  85. KURUPPU D, Brownell AL, Shah K, Mahmood U, et al
    Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.
    Cancer Res. 2014;74:4111-21.
    PubMed     Text format     Abstract available


  86. FU J, Malm IJ, Kadayakkara DK, Levitsky H, et al
    Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.
    Cancer Res. 2014;74:4042-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: